TABLE 1.
Demographics
| Pre-lumacaftor/ivacaftor | Post-lumacaftor/ivacaftor | |
|---|---|---|
| Peak ibuprofen plasma concentration(mcg/mL), mean (SD) | 84.2 (10.9) | 47.9 (16.4) |
| Average weight-based ibuprofen dose (mg/kg), mean (SD) | 23.2 (1.8) | 23.0 (1.2) |
| Average absolute ibuprofen dose (mg), mean (SD) | 744.4 (245.5) | 966.7 (300.0) |
| Average AST/ALTa, mean (SD) | 1.3 (0.4) | 1.5 (0.3) |
| Average serum creatinineb(mg/dL), mean (SD) | 0.5 (0.1) | 0.5 (0.1) |
| Average age of pharmacokinetics (years), mean (SD) | 9.7 (2.2) | 12.2 (2.0) |
| Average time from/to most recent ibuprofen kinetics (months), mean (SD) | 23.7 (16.6) | 6.4 (2.5) |
| Average age at start of lumacaftor/ivacaftor (years), mean (SD) | 11.7 (2.0) | |
| Gender, male (%) | 56 |
SD, standard deviation; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
a
Liver function tests were not available for all patients; therefore, only five patients were included in this subset.
b
Serum creatinine levels were not available for all patients; therefore, only seven patients were included in the pre-lumacaftor/ivacaftorsubset and six in the post-lumacaftor/ivacaftor subset.